Frequently, drug development has focused on tiny agents, but peptide alliances are rapidly receiving momentum. This new strategy involves combining peptides with other biological methods to tackle intricate disease mechanisms. By leveraging the specific features of amino acid sequences – such as significant selectivity and delivery – investigat